NAFAGREL

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H16N2O2
Molecular Weight	256.2997
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC2=C(CC(CN3C=CN=C3)CC2)C=C1

InChI

InChIKey=VJJHOPPXRPHVCA-UHFFFAOYSA-N

InChI=1S/C15H16N2O2/c18-15(19)14-4-3-12-7-11(1-2-13(12)8-14)9-17-6-5-16-10-17/h3-6,8,10-11H,1-2,7,9H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula	C15H16N2O2
Molecular Weight	256.2997
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://adisinsight.springer.com/drugs/800000433 | https://www.ncbi.nlm.nih.gov/pubmed/1980290 | https://www.ncbi.nlm.nih.gov/pubmed/8895147

Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Japanese normal male volunteers received repeated oral doses of 200 mg every 12 h for 4 doses, or 400 mg every 24 h for 2 doses, or 200 mg every 12 h for 14 doses.

Route of Administration: Oral

In Vitro Use Guide

In the Sephadex-induced hyperresponsiveness model, Nafagrel at the concentrations of 3 x 10(-7) to approximately 3 x 10(-6) M, reduced the augmented contraction.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:29:09 GMT 2023` Edited by `admin` on `Fri Dec 15 16:29:09 GMT 2023`
Record UNII	98PDQ9OL4V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NAFAGREL

Official Name

English

nafagrel [INN]

Common Name

English

(±)-5,6,7,8-TETRAHYDRO-6-(IMIDAZOL-1-YLMETHYL)-2-NAPHTHOIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1327